Single Center, Single Arm, Open Study, to Explore and Evaluate Treatment of Apatinib in Patients With Advanced Intrahepatic Cholangiocarcinoma
Latest Information Update: 05 Nov 2021
Price :
$35 *
At a glance
- Drugs Rivoceranib (Primary)
- Indications Cholangiocarcinoma
- Focus Therapeutic Use
- 12 Jul 2019 Status changed from recruiting to completed.
- 18 Aug 2017 New trial record